Drug Profile
AB 1005
Alternative Names: AAV2-GDNF; AAV2-GDNF-MSA; AAV2-GDNF-PD; AB-1005; Adeno-associated-virus-GDNF-therapy-Brain Neurotherapy Bio; AMT-140; GDNF gene therapy - Brain Neurotherapy Bio; Glial cell line derived neurotrophic factor gene therapy-Brain Neurotherapy BioLatest Information Update: 06 Mar 2024
Price :
$50
*
At a glance
- Originator University of California at San Francisco
- Developer Brain Neurotherapy Bio; Lund University; National Institute of Neurological Disorders and Stroke; uniQure; University of California at San Francisco
- Class Antiparkinsonians; Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Parkinson's disease
- Phase I Multiple system atrophy
Most Recent Events
- 29 Feb 2024 Asklepios Biopharmaceutical and Bayer plans to initiate a phase I (REGENERATE-PD) trial for Parkinson Disease (intraputaminal, Infusion) in April 2024 (NCT06285643)
- 17 Nov 2023 Asklepios Biopharmaceutical completes enrolment in phase Ib trial for Parkinson's disease in USA (Intracerebral) (NCT04167540)
- 29 Mar 2023 Preliminary efficacy and adverse events data from a phase I trial in Parkinson's disease presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM-2023)